Sanofi SA (SASY.PA)
20 Nov 2014
|Market Cap (Mil.):||€101,951.50|
|Shares Outstanding (Mil.):||1,326.97|
* Sees up to six new drug launches in 2015, 18 by end 2020
PARIS, Nov 20 - Sanofi Chairman Serge Weinberg to reporters on a conference call on Thursday:
PARIS - Sanofi, which sacked its chief executive three weeks ago, gave a weak sales outlook for its diabetes drugs on Thursday, overshadowing plans to reap more than 30 billion euros ($38 billion) from new medicines.
PARIS, Nov 20 - Sanofi and its U.S. partner Regeneron said on Thursday the U.S. Food and Drug Administration had designated their dupilumab drug as "breakthrough therapy" in the treatment of atopic dermatitis, a chronic form of eczema, granting the product a fast-track development and review process.
PARIS, Nov 20 - Sanofi set out its strategy for bringing several new drugs to the market on Thursday, in a bid to win over investors alarmed by the sudden ouster of its chief executive and problems in the field of diabetes.
* Fourtou to lead appointments and governance committee -source
PARIS, Nov 18 - Sanofi is drawing up a shortlist of candidates for the post of chief executive to replace Chris Viehbacher, ousted by the board last month, a source close to the French drugmaker told Reuters.
PARIS, Nov 18 - Sanofi said on Tuesday it had nominated Bonnie Bassler, a molecular biology professor, as an independent member of its board of directors.
PARIS, Nov 17 - Sanofi will hold a board meeting by telephone on Tuesday from 1100 GMT to 1200 GMT, according to two sources close to the French drugmaker.
CHICAGO - Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their "bad" LDL cholesterol down to target levels than Merck & Co's Zetia, according to data from a clinical trial presented on Monday.
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (SNY). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
"The Economy Matters" Report for SNY: the economy's impact on SNY's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
Sanofi-Aventis - Finlabo Research Equity Report: Fundamental and Technical Analysis and 6 months performance forecast
Provider: Finlabo SIM Spa
Provider: S&P Capital IQ – STARS Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.